HER-2/neu expression in Paget disease of the vulva and the female breast

Brummer, Oliver; Stegner, H.-E.; Böhmer, Gerd; Kühnle, H.; Petry, Karl Ulrich

doi:10.1016/j.ygyno.2004.07.043

Cited by 42 publications

(46 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, only limited studies evaluated the overexpression of this protein or amplification of the gene in Paget disease. [10][11][12][13] Paget disease can involve the skin of the mammary (nipple and areola) and extramammary sites (ano-vulvar and inguinal).…”

Section: Discussionmentioning

confidence: 99%

“…However, up to one-third of patients experience local recurrences within 8 years of treatment. 10,16 With the availability of the targeted therapy trastuzumab, several studies have investigated the status of HER-2/neu protein to assess the potential benefit from trastuzumab therapy in patients with extramammary Paget disease. There is inconsistency in the reported rate of HER-2/neu protein overexpression in Paget disease of vulva ranging from 0% by Meissner et al 11 to 80% by Brummer et al 10 Most studies have assessed the status of HER-2/neu protein in Paget disease of vulva, with only rare studies correlating the results with the status of the HER-2 gene.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

HER-2 Gene Amplification in Paget Disease of the Nipple and Extramammary Site: A Chromogenic In Situ Hybridization Study

Bianco

Vasef

2006

Diagnostic Molecular Pathology

View full text Add to dashboard Cite

Patients with human epidermal growth factor receptor 2 (HER-2) overexpressing breast carcinomas have a more aggressive clinical behavior and their tumors are often hormone receptor negative. However, the recently introduced anti-HER-2 antibody trastuzumab has been proven to improve the survival and controls the disease in a significant proportion of these patients. Therefore, the analysis of HER-2 in patients with breast cancer has become an important and routine test to select those who may benefit from the gene-based targeted therapy trastuzumab (herceptin). There is good correlation between HER-2/neu protein overexpression and HER-2 gene amplification in breast cancer. However, inconsistent results have been reported in the rate of HER-2/neu protein overexpression in other malignant neoplasms. Furthermore, only rare studies have investigated the correlation between the HER-2/neu protein overexpression and the status of HER-2 gene in these tumors. We investigated the HER-2 gene and protein status in several cases of Paget disease of the nipple and vulva by using a chromogenic in situ hybridization assay and immunohistochemistry. We find that the majority of the Paget disease of the breast demonstrate HER-2 gene amplification, whereas most of the extramammary Paget disease lack HER-2 gene amplification. In addition, our results show a good correlation between HER-2/neu protein overexpression and HER-2 gene amplification in Paget disease of the nipple, but we were unable to confirm this correlation in HER-2/neu protein overexpressing Paget disease of the vulva.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

HER-2 Gene Amplification in Paget Disease of the Nipple and Extramammary Site: A Chromogenic In Situ Hybridization Study

Bianco

Vasef

2006

Diagnostic Molecular Pathology

View full text Add to dashboard Cite

show abstract

“…Brummer et al [159] detected overexpression of HER-2/neu in 8 (80%) out of 10 cases of vulvar Paget's disease (7 noninvasive lesions, 2 invasive lesions, and 1 lesion with underlying adenocarcinoma) as well as in all 5 cases of mammary Paget's disease, thus suggesting the possible use of trastuzumab for the treatment of selected patients with recurrent vulvar Paget's disease.…”

Section: Invasive Paget's Disease or Intraepithelial Paget's Disease mentioning

confidence: 99%

Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer

Gadducci

Cionini

Romanini

et al. 2006

Critical Reviews in Oncology/Hematology

104

View full text Add to dashboard Cite

“…It is thought that the spread of Paget's cells is induced by a motility factor that acts through the Her-2 receptor. However, there is inconsistency in the reported rates of Her-2 protein overexpression in EMPD, ranging from 0 to 80% [25,26]. Takata et al [24] showed that Her-2 overexpression was more frequent in invasive EMPD than in non-invasive lesions.…”

mentioning

confidence: 99%